PreprintCommunicationVersion 1Preserved in Portico This version is not peer-reviewed
Sorafenib Analogue and Its Rearranged Compound: Design, Synthesis, Their In Vitro Anticancer Activity and Crystal Structure of the Rearranged Compound Dichloromethane Solvate
Version 1
: Received: 23 January 2024 / Approved: 24 January 2024 / Online: 24 January 2024 (09:52:57 CET)
How to cite:
Yu, Q. Sorafenib Analogue and Its Rearranged Compound: Design, Synthesis, Their In Vitro Anticancer Activity and Crystal Structure of the Rearranged Compound Dichloromethane Solvate. Preprints2024, 2024011715. https://doi.org/10.20944/preprints202401.1715.v1
Yu, Q. Sorafenib Analogue and Its Rearranged Compound: Design, Synthesis, Their In Vitro Anticancer Activity and Crystal Structure of the Rearranged Compound Dichloromethane Solvate. Preprints 2024, 2024011715. https://doi.org/10.20944/preprints202401.1715.v1
Yu, Q. Sorafenib Analogue and Its Rearranged Compound: Design, Synthesis, Their In Vitro Anticancer Activity and Crystal Structure of the Rearranged Compound Dichloromethane Solvate. Preprints2024, 2024011715. https://doi.org/10.20944/preprints202401.1715.v1
APA Style
Yu, Q. (2024). Sorafenib Analogue and Its Rearranged Compound: Design, Synthesis, Their In Vitro Anticancer Activity and Crystal Structure of the Rearranged Compound Dichloromethane Solvate. Preprints. https://doi.org/10.20944/preprints202401.1715.v1
Chicago/Turabian Style
Yu, Q. 2024 "Sorafenib Analogue and Its Rearranged Compound: Design, Synthesis, Their In Vitro Anticancer Activity and Crystal Structure of the Rearranged Compound Dichloromethane Solvate" Preprints. https://doi.org/10.20944/preprints202401.1715.v1
Abstract
Cancer is a devastating disease with female breast cancer becoming the leading cause of global cancer morbidity. Herein we report the design and synthesis of a sorafenib analog 1A and its base-promoted arranged compound 1A2. Their in vitro cytotoxicity and potencies in EFGR inhibition study revealed that compound 1A displayed good antiproliferative activity in MDA-MB-231 (breast) cells with an IC50 value of 16.18±1.42 μM. Crystallization 1A2 affored 1A2a as a solvate with dichloromethane which was explicitly confirmed by the single crystal X-ray diffraction analysis.
Chemistry and Materials Science, Medicinal Chemistry
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
